0000000000141540

AUTHOR

Emanuela Arvat

showing 3 related works from this author

Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

2017

urpose Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results We identified eight retrospective published studies, two prospective published studies…

0301 basic medicinemTOR inhibitorsCancer Researchmedicine.medical_specialtyPathologymTOR inhibitorEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Oncology; Cancer ResearchTherapeutic algorithmEverolimus; mTOR inhibitors; neuroendocrine tumours; therapy; antineoplastic agents; everolimus; humans; neuroendocrine tumours; pancreatic neoplasms; oncology; cancer researchEndocrine SyndromeNeuroendocrine tumorsAntineoplastic Agent03 medical and health sciences0302 clinical medicineFirst line therapyNeuroendocrine tumourantineoplastic agentsmedicinehumansIntensive care medicinetherapyEverolimusbusiness.industryPancreatic Neoplasmpancreatic neoplasmsGeneral Medicineeverolimusmedicine.diseaseDiscovery and development of mTOR inhibitorsClinical trialEverolimuNeuroendocrine Tumors030104 developmental biologyOncology030220 oncology & carcinogenesisneuroendocrine tumoursNeuroendocrine TumorbusinessEverolimus; mTOR inhibitors; Neuroendocrine tumours; Therapy; Antineoplastic Agents; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic NeoplasmsHumanmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neur…

2020

Introduction The organization of the healthcare system has significantly changed after the recent COVID-19 outbreak, with a negative impact on the management of oncological patients. The present survey reports data collected by the Italian Association for Neuroendocrine Tumors on the management of patients with neuroendocrine neoplasia (NEN) during the pandemic dissemination. Methods A survey with 57 questions was sent to NEN-dedicated Italian centers regarding the management of patients in the period March 9, 2020, to May 9, 2020 Results The main modification in the centers’ activity consisted of decreases in newly diagnosed NEN patients (− 76.8%), decreases in performed surgical procedure…

AdultMalePediatricsmedicine.medical_specialtyEndocrinology Diabetes and MetabolismAntineoplastic Agents030209 endocrinology & metabolismNeuroendocrine tumorsMedical OncologyNO03 medical and health sciencesPatient safety0302 clinical medicineEndocrinologyAmbulatory careNeuroendocrine tumorSurveys and QuestionnairesEpidemiologyPandemicHumansMedicineLS4_3PandemicsPatient Care TeamPandemicbusiness.industryCOVID-19Multidisciplinary teamContinuity of Patient Caremedicine.diseaseManagementClinical trialItalyCOVID-19; management; multidisciplinary team; neuroendocrine tumors; pandemic; peptide receptors radionuclide therapy; SARS-CoV2030220 oncology & carcinogenesisRadionuclide therapySARS-CoV2s COVID-19 SARS-CoV2 Pandemic Neuroendocrine tumors Multidisciplinary team Management Peptide receptors radionuclide therapyPeptide receptors radionuclide therapyOriginal ArticleFemaleneuroendocrine tumorsbusinessHealth care quality
researchProduct

The treatment of hyperinsulinemic hypoglycaemia in adults: an update

2016

Treatment of hyperinsulinemic hypoglycaemia (HH) is challenging due to the rarity of this condition and the difficulty of differential diagnosis. The aim of this article is to give an overview of the recent literature on the management of adult HH. A search for reviews, original articles, original case reports between 1995 and 2016 in PubMed using the following keywords: hyperinsulinemic hypoglycaemia, insulinoma, nesidioblastosis, gastric bypass, autoimmune hypoglycaemia, hyperinsulinism, treatment was performed. One hundred and forty articles were selected and analysed focusing on the most recent treatments of HH. New approaches to treatment of HH are available including mini-invasive sur…

Adultmedicine.medical_specialtyPediatricsendocrine system diseasesEndocrinology Diabetes and MetabolismGastric bypassNesidioblastosis030209 endocrinology & metabolismHypoglycemiaSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyHyperinsulinismmedicineHyperinsulinemic hypoglycaemiaHumansAutoimmune hypoglycaemiaInsulinomaEverolimusbusiness.industryAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment; Adult; Humans; Hyperinsulinism; HypoglycemiaAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment; Adult; Humans; Hyperinsulinism; Hypoglycemia; Endocrinology Diabetes and Metabolism; EndocrinologySettore MED/13 - ENDOCRINOLOGIANesidioblastosimedicine.diseaseHypoglycemiaSurgeryDiabetes and MetabolismTreatmentNesidioblastosisAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment030220 oncology & carcinogenesisAutoimmune hypoglycaemiaInsulinomaAutoimmune hypoglycaemia; Hyperinsulinemic hypoglycaemia; Insulinoma; Nesidioblastosis; Treatment; Endocrinology Diabetes and Metabolism; EndocrinologyDifferential diagnosisbusinessHyperinsulinismhormones hormone substitutes and hormone antagonistsmedicine.drugHuman
researchProduct